Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05879822	TitleEstudio para evaluar INCB099280 en participantes con tumores sólidos seleccionados que no han recibido ningún inhibidor de los puntos de control inmunitarios.	Fase Fase 2	Date Added 2023-05-30	Ubicación Brasil China Georgia Greece Hungary Nueva Zelanda Romania Sudáfrica Turkey	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas INCB099280	Etiquetas MSI-H/ MMRd
NCT ID NCT05865535	TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia	Fase Fase 1	Date Added 2023-05-19	Ubicación California, United States Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05838768	TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	Fase Fase 1	Date Added 2023-05-03	Ubicación California, United States Massachusetts, United States New York, United States Texas, United States Bélgica China Francia Alemania Israel Italia Japón Corea, República de Noruega Singapur España Suecia Taiwán Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas HRO761, Irinotecan	Etiquetas MSI-H/ MMRd
NCT ID NCT05799443	TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer	Fase Fase 2	Date Added 2023-04-05	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas cetuximab, Irinotecan Hydrochloride, Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05798533	TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)	Fase Fase 1	Date Added 2023-04-04	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Cyclophosphamide, Fludarabine, Interleukin-2	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05785325	TitleRC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo	Fase Fase 2	Date Added 2023-03-27	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas RC48-ADC más Bevacizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05784688	TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Fase Phase 1, Phase 2	Date Added 2023-03-27	Ubicación Texas, United States Washington, United States Corea, República de	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas TU2218 + Pembrolizumab	Etiquetas MSS/ MMRp
NCT ID NCT05783089	TitleMSLN-targeted CAR-T Cells in Solid Tumors.	Fase Fase 1	Date Added 2023-03-24	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05771181	TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients	Fase Fase 2	Date Added 2023-03-16	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas Fruquintinib, Tislelizumab, Vitamin E	Etiquetas MSS/ MMRp
NCT ID NCT05770102	TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Fase Fase 2	Date Added 2023-03-15	Ubicación Reino Unido	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas Atezolizumab	Etiquetas MSI-H/ MMRd

Showing 61 to 70 of 299 entries